News

Belharra and Sanofi entered into a strategic collaboration leveraging Belharra’s proprietary chemoproteomics platform to identify and advance small molecules against Sanofi-designated immunology targets. Under the terms of the agreement, Belharra is eligible to receive up to $40 million in upfront and near-term milestone payments. Read press release.